ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress

- Results of Phase III clinical studies highlight benefits of ACTEMRA as a treatment for rheumatoid arthritis - NUTLEY, N.J., June 4 /PRNewswire/ -- Roche today announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinica...

No link between bad weather and rheumatism

People with some forms of rheumatism say that weather conditions can affect their disease symptoms, but new research suggests this is not the case.// The study focused on women with the chronic rheumatic condition fibromyalgia, which is characterised by pain and stiffness in the muscles, joints and...

Sunlight May Cause Rash in Autoimmune Disease

...mmune diseases and autoantibodies in women," Miller said in the news release. The study appears in the August issue of the journal Arthritis & rheumatism . More information The U.S. National Library of Medicine has more about myositis . -- Robert Preidt ...

Flu Shot May Be Less Effective in Those With Lupus

...ndings. But the study, published in the August issue of Arthritis & rheumatism , also found that the activity of those T-cells key to immunization were di... -- E.J. Mundell SOURCE: Arthritis & rheumatism , news release, July 30, 2009 ...

Sun exposure may trigger certain autoimmune diseases in women

...the frequency of dermatomyositis that we found in a previous investigation," said Miller. The study, published in the August issue of Arthritis & rheumatism , is also the first to evaluate and find a possible UV radiation association in autoimmune diseases in women. According to Miller, women are more lik...

Biomarker Could Predict Severe Osteoarthritis

...tients. The study, which appears in the August issue of Arthritis & rheumatism , is the first to establish a laboratory biomarker for the risk of severe o... -- Robert Preidt SOURCE: Arthritis & rheumatism , news release, July 30, 2009 ...

Protein level may serve as predictor of severe osteoarthritis

...ule 1 (VCAM-1), was a strong predictor of hip and knee joint replacement due to severe OA. The study was published in the August issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ). Led by Georg Schett of the University of Erlangen-Nuremberg in Erlangen, Germany, the s...

Immune responses to flu vaccine are diminished in lupus patients

...mine cell-mediated responses in SLE patients prior to and following influenza vaccination. The study was published in the August issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ). Led by Albert Holvast, of the University of Groningen in The Netherlands, the study invo...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results

...t enrollment is expected to begin in the third quarter of 2009. In addition, Lexicon presented Phase 1 data for LX2931 at the European League Against rheumatism (EULAR) annual meeting on June 13, 2009. Lexicon continues to enroll patients in a Phase 2a clinical trial of its LX1031 drug candidate for ...

Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments

...2009, results through four years of the long-term Phase 2 continuation study of BENLYSTA were presented at the Congress of the European League against rheumatism (EULAR). The data showed that BENLYSTA was associated with sustained improvement in SLE disease activity and patient response rates, decreased freque...

Rheumatism in Medical Technology

Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

First of Phase 2b studies completes patient screening for enrollment SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the previously reported results of the Phase 2 clinical trial of R788 (fostamatinib disodium),...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

...of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline. These data were presented at the 2009 European League Against rheumatism (EULAR) Annual Congress. Findings from the GO limumab A fter F ormer anti-TNF T herapy E valuated in R A (GO-AFTER) study, demonstrated t...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

...Investigators reported these new data from the long term treatment extensions of the GO-REVEAL and GO-RAISE trials at the 2009 European League Against rheumatism (EULAR) Annual Congress. In the Go limumab - A R andomized EV aluation of Safety and E fficacy in Subjects with Psoriatic A rthritis Using...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

...amage compared with patients treated with methotrexate alone. These data will be presented at the 10th Annual Congress of the European League Against rheumatism (EULAR) in Copenhagen, Denmark, along with additional studies that support the use of ACTEMRA as a long-term treatment option for patients with modera...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

...rnational scientific meeting. One-year LITHE data have been accepted for presentation at the 10th Annual Congress of the European League Against rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark. About the LITHE Study The LITHE study was a three-arm, randomized,...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

...h methotrexate, and no drug-drug interactions were observed. In addition, Lexicon will present Phase 1 data for LX2931 at the European League Against rheumatism (EULAR) annual meeting on June 13, 2009. Lexicon continues to enroll patients in a Phase 2a clinical trial of its LX1031 drug candidate f...

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

...ent that may increase the rate of serious cardiovascular adverse events. The new results are being presented today at the 2008 European League Against rheumatism (EULAR) Congress in Paris. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donato...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

...ulations - MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumo...

Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594

... - RDEA594 Data to Be Presented at the 2008 Annual European Congress of Rheumatology Organized by the European League Against rheumatism (EULAR) - - Initiation of Phase 1 Human Study of RDEA594 Planned in Second Half of 2008 - SAN DIEGO, May 19 /PRNew...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

...y is interpreted as low (DAS28 moderate (3.2 5.1). DAS28 corresponds to being in remission according to the criteria of the American rheumatism Association (ARA). (3) The EULAR response criteria is based on the individual amount of change in DAS and the DAS value (low, moderate, high dis...

Rheumatism in Medical Dictionary

Rheumatism

Rheumatism or rheumatic disorder is a non-specific term for medical problems affecting the joints and connective tissue. The study of, and therapeutic interventions in, such disorders is called rheumatology. Information on Rheumatism causes and Rheumatism symptoms ... The word rheuma...

Interstitial nephritis

...temporary (acute) or it may be chronic and ... Interstitial nephritis can cause mild to severe kidney problems, including acute ... ... rheumatism is sometimes followed by interstitial nephritis , while malaria ... In fact, in treating interstitial nephritis , we treat our patient ... ...

Rheumatism in Biological News

Gene expression findings a step toward better classification and treatment of juvenile arthritis

...types we currently recognize," Dr. Colbert says. In the first of two such NIAMS-supported studies to be published in the July issue of Arthritis & rheumatism , scientists led by Michael Barnes, Ph.D., of Cincinnati Children's Hospital Medical Center used a large data set to compare a number of children newl...

8 plants from South Africa may hold potential for treating high blood pressure

...c." Researchers have recorded (1962) that the plant was pounded into formulations and used by native South Africans to relieve stomach ailments, rheumatism and high fevers. Other researchers found (1966) that native South Africans rubbed the leaves of the plant on the head for sinus headaches and used pla...

New insights into autoimmunity and depression

...esearchers at Tel Aviv University set out to induce depressive hallmarks in mice. Their findings, presented in the March 2007 issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ), shed light on the brain pathways of depression in general and in central nervous system dysfu...

New genes implicated in rheumatoid arthritis

...iversity of Michigan Medical Center turned to an ideal population: genetically identical, disease-discordant twins. The July issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ) highlights the results of their state-of-the-art genetic analysis. ...

Stem cells from muscles can repair cartilage

... develop in various ways, including into cells that lead to the formation of bone. In a study published in the February 2006 issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ), researchers designed a study using muscle-derived stem cells (MDSCs) genetically engineered w...

Rheumatism in Biological Technology

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

...lly active systemic lupus erythematosus (SLE). The results were presented today in Copenhagen at the 2009 Congress of the European League Against rheumatism (EULAR). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "Based on the results presented at EULAR 2009, the apparent du...

New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives

...Despite Current Treatment; Findings Unveiled at the European League Against rheumatism Annual Congress of Rheumatology COPENHAGEN, Denmark, June 10 /PRNewswi...s were accepted for poster presentation at the 2009 European League Against rheumatism (EULAR) Annual Congress of Rheumatology in Copenhagen. The RAISE surve...

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

...ntific congresses in 2008 and sponsored 3 symposia: at the American Heart Association (AHA) annual meeting in New Orleans, the European League Against rheumatism (EULAR) annual meeting in Paris, and the Osteoarthritis Research Society International (OARSI) congress in Rome. All these events gave NicOx' scientis...

Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring

...ation in 2010 -- Announce TRU-015 Phase 2b (15002) rheumatoid arthritis re-treatment data at the annual meetings of the European League Against rheumatism and the American College of Rheumatology (ACR) -- Announce TRU-015 Phase 2b (2203) rheumatoid arthritis trial data by end of Q4 2009 (currently...

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

... (5) Chappell, AS, et al. A 1-Year Safety and Efficacy Study of Duloxetine in Patients with Fibromyalgia. Poster presented at European League Against rheumatism Annual Meeting; Jun 2008, Paris, France. (6) Leventhal, LJ. Management of Fibromyalgia. Annals of Internal Medicine. 1999; 131: 850-858. (7) Arnol...

Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

... HGS and GSK under a co-development and commercialization agreement entered into in August 2006. At the 2008 Congress of the European League Against rheumatism (EULAR) in June, the Company presented three-year data from a long-term Phase 2 continuation trial demonstrating that belimumab was associated with su...

Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout

...ez-Ruiz is a member of the American College of Rheumatology and Spanish Society for Rheumatology and has collaborated with the European League Against rheumatism (EULAR) Task Force for Gout and with the Outcome Measures for Rheumatic Arthritis Clinical Trials (OMERACT) group for chronic gout. He serves on the e...

Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis

...ulations MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tum...

Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... of golimumab in the treatment of more than 1,400 adults with moderate to severe rheumatoid arthritis will be presented at the European League Against rheumatism Annual Congress in June 2008. About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic and debilitating disease that affects approximatel...

Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)

...d injection of Synvisc-One six months after the first injection. Data from the study were presented earlier this year at the European League Against rheumatism annual meeting in Barcelona, Spain and have been accepted for a podium presentation at the American Association of Orthopaedic Surgeons annual meeting...